64
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Hydrocarbon-Stapled Peptides: Principles, Practice, and Progress : Miniperspective

      review-article
      , , § , , , ,
      Journal of Medicinal Chemistry
      American Chemical Society

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Protein structure underlies essential biological processes and provides a blueprint for molecular mimicry that drives drug discovery. Although small molecules represent the lion’s share of agents that target proteins for therapeutic benefit, there remains no substitute for the natural properties of proteins and their peptide subunits in the majority of biological contexts. The peptide α-helix represents a common structural motif that mediates communication between signaling proteins. Because peptides can lose their shape when taken out of context, developing chemical interventions to stabilize their bioactive structure remains an active area of research. The all-hydrocarbon staple has emerged as one such solution, conferring α-helical structure, protease resistance, cellular penetrance, and biological activity upon successful incorporation of a series of design and application principles. Here, we describe our more than decade-long experience in developing stapled peptides as biomedical research tools and prototype therapeutics, highlighting lessons learned, pitfalls to avoid, and keys to success.

          Related collections

          Most cited references42

          • Record: found
          • Abstract: found
          • Article: not found

          MDM4 is a key therapeutic target in cutaneous melanoma.

          The inactivation of the p53 tumor suppressor pathway, which often occurs through mutations in TP53 (encoding tumor protein 53) is a common step in human cancer. However, in melanoma-a highly chemotherapy-resistant disease-TP53 mutations are rare, raising the possibility that this cancer uses alternative ways to overcome p53-mediated tumor suppression. Here we show that Mdm4 p53 binding protein homolog (MDM4), a negative regulator of p53, is upregulated in a substantial proportion (∼65%) of stage I-IV human melanomas and that melanocyte-specific Mdm4 overexpression enhanced tumorigenesis in a mouse model of melanoma induced by the oncogene Nras. MDM4 promotes the survival of human metastatic melanoma by antagonizing p53 proapoptotic function. Notably, inhibition of the MDM4-p53 interaction restored p53 function in melanoma cells, resulting in increased sensitivity to cytotoxic chemotherapy and to inhibitors of the BRAF (V600E) oncogene. Our results identify MDM4 as a key determinant of impaired p53 function in human melanoma and designate MDM4 as a promising target for antimelanoma combination therapy.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Synthesis of all-hydrocarbon stapled α-helical peptides by ring-closing olefin metathesis.

            This protocol provides a detailed procedure for the preparation of stapled α-helical peptides, which have proven their potential as useful molecular probes and as next-generation therapeutics. Two crucial features of this protocol are (i) the construction of peptide substrates containing hindered α-methyl, α-alkenyl amino acids and (ii) the ring-closing olefin metathesis (RCM) of the resulting resin-bound peptide substrates. The stapling systems described in this protocol, namely bridging one or two turns of an α-helix, are highly adaptable to most peptide sequences, resulting in favorable RCM kinetics, helix stabilization and promotion of cellular uptake.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic.

              The pharmacologic utility of lengthy peptides can be hindered by loss of bioactive structure and rapid proteolysis, which limits bioavailability. For example, enfuvirtide (Fuzeon, T20, DP178), a 36-amino acid peptide that inhibits human immunodeficiency virus type 1 (HIV-1) infection by effectively targeting the viral fusion apparatus, has been relegated to a salvage treatment option mostly due to poor in vivo stability and lack of oral bioavailability. To overcome the proteolytic shortcomings of long peptides as therapeutics, we examined the biophysical, biological, and pharmacologic impact of inserting all-hydrocarbon staples into an HIV-1 fusion inhibitor. We find that peptide double-stapling confers striking protease resistance that translates into markedly improved pharmacokinetic properties, including oral absorption. We determined that the hydrocarbon staples create a proteolytic shield by combining reinforcement of overall alpha-helical structure, which slows the kinetics of proteolysis, with complete blockade of peptide cleavage at constrained sites in the immediate vicinity of the staple. Importantly, double-stapling also optimizes the antiviral activity of HIV-1 fusion peptides and the antiproteolytic feature extends to other therapeutic peptide templates, such as the diabetes drug exenatide (Byetta). Thus, hydrocarbon double-stapling may unlock the therapeutic potential of natural bioactive polypeptides by transforming them into structurally fortified agents with enhanced bioavailability.
                Bookmark

                Author and article information

                Journal
                J Med Chem
                J. Med. Chem
                jm
                jmcmar
                Journal of Medicinal Chemistry
                American Chemical Society
                0022-2623
                1520-4804
                19 February 2015
                19 February 2014
                14 August 2014
                : 57
                : 15
                : 6275-6288
                Affiliations
                []Department of Pediatric Oncology, Dana-Farber Cancer Institute , Boston, Massachusetts 02215, United States
                []Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute , Boston, Massachusetts 02215, United States
                [§ ]Department of Pediatrics, Children’s Hospital Boston, Harvard Medical School , Boston, Massachusetts 02115, United States
                Author notes
                [* ]L.D.W.: (address) Dana-Farber Cancer Institute, 450 Brookline Avenue, Mayer 664, Boston, MA 02215; (phone, office) 617-632-6307; (fax) 617-582-8240; (e-mail) loren_walensky@ 123456dfci.harvard.edu .
                [* ]G.H.B.: (address) Dana-Farber Cancer Institute, 1 Jimmy Fund Way, Smith 758, Boston, MA 02215; (phone, office) 617-582-8517; (e-mail) greg_bird@ 123456dfci.harvard.edu .
                Article
                10.1021/jm4011675
                4136684
                24601557
                fe856eef-dbaa-4bd5-830c-c363bf15ac24
                Copyright © 2014 American Chemical Society

                Terms of Use

                History
                : 31 July 2013
                Funding
                National Institutes of Health, United States
                Categories
                Perspective
                Custom metadata
                jm4011675
                jm-2013-011675

                Pharmaceutical chemistry
                Pharmaceutical chemistry

                Comments

                Comment on this article